HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

972.603

-4.817-0.49%

Number of Gainers:2

Number of Losers:16

Number of Flat:- -

PE:- -

High:979.553

Open:977.343

Low:962.881

Close:977.420

Loading ...

CSPC Pharmaceutical Gets China Nod for Registration of Anemia Drug

MT Newswires Live

CSPC Pharmaceutical Group Ltd. Secures Drug Registration Approval for Cobamamide Capsules in China

CSPC Pharmaceutical - Cobamamide Capsules Obtain Drug Registration Approval From Nmpa

THOMSON REUTERS

Sino Biopharm Presents Lung Cancer Drug Trial Data at US Oncology Conference

MT Newswires Live

BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As Chairman

Tong Ren Tang Technologies Co Ltd - Resignation of Di Shu Bing as Chairman of Board

THOMSON REUTERS

China Traditional Chinese Medicine Holdings Co. Limited Announces Special Dividend of HK8.30 Cents and Final Dividend of HK0.35 Cent Per Share

BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China

Sagimet Biosciences Shares Jump 52% Premarket After Oral Acne Drug With Partner Ascletis Met the Main Goals in a Late-Stage Trial

THOMSON REUTERS

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne

Ascletis Pharma Announces Successful Phase III Trial of Denifanstat, a Groundbreaking Oral FASN Inhibitor for Acne Treatment

Ascletis Announces Phase Iii Trial of Denifanstat (Asc40), a First-in-Class, Once-Daily Oral Fasn Inhibitor for Acne, Meets All Endpoints

THOMSON REUTERS

Ascletis Pharma Inc - Announces Phase Iii Trial of Denifanstat Meets All Endpoints

THOMSON REUTERS

Sino Biopharm Presents Lung Cancer Study Data at American Oncology Conference

MT Newswires Live

CSPC Pharmaceutical Group Announces Breakthrough Therapy Designation for JMT101 in Advanced Colorectal Cancer Treatment

Fosun Pharma's Respiratory Drug Receives Clinical Trial Approval for COPD Treatment in China

MT Newswires Live

CSPC Pharmaceutical - Jmt101 Granted Breakthrough Therapy Designation by Nmpa

THOMSON REUTERS

CSPC Pharmaceutical Group May Benefit From Higher Success Odds of 'SYS6010' -- Market Talk

Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs

Fosun Pharmaceutical Gets Chinese Regulatory Approval for Breast Cancer Drug; Shares Up 4%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":972.6025,"timestamp":1749189501049,"preClose":977.4198,"halted":0,"volume":468934075,"delay":0,"changeRate":-0.004929,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-4.817322,"latestTime":"06-06 13:58:21","open":977.34314,"high":979.5527,"low":962.88086,"amount":3241499138,"amplitude":0.017057,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749197400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":1.687745,"peRate":22.554204,"turnoverRate":0.00637,"increases":2,"decrements":16,"flats":0,"marketCap":672677281344,"floatMarketCap":551383249856},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":979.5527,"amplitude":0.017057,"preClose":977.4198,"low":962.88086,"pbRate":"1.687745","latestPrice":972.6025,"volume":468934075,"delay":0,"open":977.34314,"prevYearClose":787.97723,"prevWeekClose":975.506,"prevMonthClose":975.506,"prevQuarterClose":870.015,"fiveDayClose":975.506,"twentyDayClose":896.528,"sixtyDayClose":938.742,"secType":"PLATE","market":"HK","turnoverRate":0.00637,"peRate":22.554204,"marketCap":672677281344,"floatMarketCap":551383249856,"timestamp":1749189501049,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":2,"down":16,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541027976","title":"CSPC Pharmaceutical Gets China Nod for Registration of Anemia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2541027976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541027976?lang=en_us&edition=fundamental","pubTime":"2025-06-05 19:46","pubTimestamp":1749123978,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  obtained drug registration approval for its Cobamamide capsules from China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.The move came after the product was deemed to pass the consistency evaluation of quality and efficacy of generic drugs.The product is a type of vitamin B12 drug indicated for the treatment of megaloblastic anemia, nutritional anemia, anemia during pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve palsy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0008369823.USD","BK1191","SG9999004220.SGD","LU1993786604.SGD","LU0880133367.SGD","LU1008478684.HKD","LU0326950275.SGD","LU1951186391.HKD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1226287529.USD","LU0072913022.USD","LU1226287875.USD","LU1960683339.HKD","BK1521","LU0501845795.SGD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU0067412154.USD","LU1152091754.HKD","LU1226288253.USD","LU0140636845.USD","LU1152091168.USD","IE00BZ08YR35.GBP","BK1515","LU1807302812.USD","LU1226288170.HKD","IE00B543WZ88.USD","01093","IE00B031HY20.USD","IE0008368742.USD"],"gpt_icon":1},{"id":"2541029723","title":"CSPC Pharmaceutical Group Ltd. Secures Drug Registration Approval for Cobamamide Capsules in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2541029723","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541029723?lang=en_us&edition=fundamental","pubTime":"2025-06-05 18:05","pubTimestamp":1749117903,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited has announced that its Cobamamide Capsules  have received drug registration approval from the National Medical Products Administration of the People's Republic of China. This approval marks a significant addition to the company's product offerings in the therapeutic areas of hematology and neurology. Cobamamide Capsules, a form of vitamin B12, are indicated for treating various types of anemia, nerve-related conditions, and may serve as an adjunct therapy for nutritional disorders and leukopenia caused by radiation and drugs. The approval confirms the product's compliance with the quality and efficacy standards for generic drugs. This development further enhances CSPC Pharmaceutical Group's portfolio and commitment to advancing healthcare solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDLzG86j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288253.USD","IE00B543WZ88.USD","SG9999004220.SGD","LU0072913022.USD","LU1226287875.USD","LU1951186391.HKD","IE00BZ08YT58.USD","LU1226287792.SGD","LU1226288170.HKD","LU1960683339.HKD","LU0501845795.SGD","LU0880133367.SGD","01093","LU1807302812.USD","LU1008478684.HKD","LU1152091168.USD","LU0140636845.USD","LU0326950275.SGD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1226287529.USD","IE0008369823.USD","IE0008368742.USD","BK1191","IE00B031HY20.USD","LU0067412154.USD","BK1515","LU1152091754.HKD","LU1993786604.SGD","BK1521","IE00B5MMRT66.SGD"],"gpt_icon":1},{"id":"2541029279","title":"CSPC Pharmaceutical - Cobamamide Capsules Obtain Drug Registration Approval From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2541029279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541029279?lang=en_us&edition=fundamental","pubTime":"2025-06-05 18:02","pubTimestamp":1749117755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S7122:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B031HY20.USD","01093","LU1993786604.SGD","BK1521","LU1152091754.HKD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU1008478684.HKD","IE00BZ08YT58.USD","LU0326950275.SGD","IE0008368742.USD","LU0067412154.USD","LU0880133367.SGD","IE0008369823.USD","LU1807302812.USD","LU0501845795.SGD","BK1191","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU1226288253.USD","LU1226287875.USD","LU0072913022.USD","IE00B5MMRT66.SGD","LU1951186391.HKD","LU1152091168.USD","BK1515","SG9999004220.SGD","LU1226287529.USD","LU0140636845.USD","LU1226288170.HKD","LU1960683339.HKD"],"gpt_icon":0},{"id":"2541446500","title":"Sino Biopharm Presents Lung Cancer Drug Trial Data at US Oncology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2541446500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541446500?lang=en_us&edition=fundamental","pubTime":"2025-06-05 16:08","pubTimestamp":1749110917,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical (HKG:1177) presented the latest results of the phase III clinical study of its benmelstobart injection at the 2025 American Society of Clinical Oncology Annual Meeting, a Thursd","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","IE00BZ08YS42.EUR","BK1589","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","01177","BK1521","BK1515"],"gpt_icon":0},{"id":"2541092127","title":"BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2541092127","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541092127?lang=en_us&edition=fundamental","pubTime":"2025-06-05 07:01","pubTimestamp":1749078081,"startTime":"0","endTime":"0","summary":"BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As ChairmanJune 5 (Reuters) - Tong Ren Tang Technologies Co Ltd 1666.HK:RESIGNATION OF DI SHU BING AS CHAIRMAN OF BOARDFurther company coverage: 1666.HK ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S7109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01666","BK1583","BK1606","BK1515","BK1191"],"gpt_icon":0},{"id":"2541929180","title":"Tong Ren Tang Technologies Co Ltd - Resignation of Di Shu Bing as Chairman of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2541929180","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541929180?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:59","pubTimestamp":1749077956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S7109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1606","BK1191","BK1583","01666"],"gpt_icon":0},{"id":"2540064308","title":"China Traditional Chinese Medicine Holdings Co. Limited Announces Special Dividend of HK8.30 Cents and Final Dividend of HK0.35 Cent Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2540064308","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540064308?lang=en_us&edition=fundamental","pubTime":"2025-06-04 22:13","pubTimestamp":1749046381,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited Announces Special Dividend of HK8.30 Cents and Final Dividend of HK0.35 Cent Per Share. China Traditional Chinese Medicine Holdings Co. Limited announced a final dividend of HK0.35 cent per share and a special dividend of HK8.30 cents per share for the year ended 31 December 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL3xh0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570","BK1191","BK1515","BK1606"],"gpt_icon":0},{"id":"2540055112","title":"BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2540055112","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540055112?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:27","pubTimestamp":1749029233,"startTime":"0","endTime":"0","summary":"BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China** Shares of drug developer Sagimet Biosciences SGMT.O rise 52% to $5.53 premarket** SGMT says its oral acne drug, denifanstat, met the main goals in a late-stage trial conducted by its Chinese partner Ascletis 1672.HK** Denifanstat showed 33.2% treatment success rate versus 14.6% for placebo** Denifanstat works by inhibiting the production of sebum, a key contributor to acne, through a novel mechanism of action, co says** The drug reduced total acne lesions by 57.4% compared to 35.4% with placebo** Ascletis plans to submit denifanstat for approval to Chinese regulators** As of last close, stock down 19.3% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nL3N3S70LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1515","BK1161","BK1574","01672","SGMT"],"gpt_icon":0},{"id":"2540055977","title":"Sagimet Biosciences Shares Jump 52% Premarket After Oral Acne Drug With Partner Ascletis Met the Main Goals in a Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540055977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540055977?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:15","pubTimestamp":1749028555,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK1515","BK1161","BK4139","BK1574","01672"],"gpt_icon":0},{"id":"2540053848","title":"Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2540053848","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540053848?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:00","pubTimestamp":1749027616,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase  inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9NgkYx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","BK1515","IE00BKPKM429.USD","BK1161","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4112","LU2210150020.SGD","01672","LU2095319765.USD","BK4585","LU2210149790.SGD","BK1574","SGMT","BK4588","NDAQ"],"gpt_icon":0},{"id":"2540088442","title":"Ascletis Pharma Announces Successful Phase III Trial of Denifanstat, a Groundbreaking Oral FASN Inhibitor for Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540088442","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540088442?lang=en_us&edition=fundamental","pubTime":"2025-06-04 07:15","pubTimestamp":1748992517,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has announced that its Phase III clinical trial for denifanstat , a first-in-class, once-daily oral fatty acid synthase  inhibitor, has met all primary, key secondary, and secondary endpoints for the treatment of moderate to severe acne vulgaris. The randomized, double-blind, placebo-controlled, multicenter trial conducted in China involved 480 patients. Denifanstat demonstrated a statistically significant improvement in treatment outcomes, with a 33.2% treatment success rate and reductions in total, inflammatory, and non-inflammatory lesion counts by 57.4%, 63.5%, and 51.9% respectively, compared to baseline. The trial results indicate that denifanstat was more effective than several FDA-approved acne treatments in placebo-adjusted percent treatment success. The drug maintained a favorable safety and tolerability profile throughout the study. Ascletis plans to submit the treatment for approval by the China National Medical Products Administration .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL63QMGf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","01672"],"gpt_icon":0},{"id":"2540088448","title":"Ascletis Announces Phase Iii Trial of Denifanstat (Asc40), a First-in-Class, Once-Daily Oral Fasn Inhibitor for Acne, Meets All Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2540088448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540088448?lang=en_us&edition=fundamental","pubTime":"2025-06-04 07:15","pubTimestamp":1748992502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA3LVHCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"gpt_icon":0},{"id":"2540088939","title":"Ascletis Pharma Inc -  Announces Phase Iii Trial of Denifanstat Meets All Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2540088939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540088939?lang=en_us&edition=fundamental","pubTime":"2025-06-04 07:00","pubTimestamp":1748991657,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60FU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"2540779995","title":"Sino Biopharm Presents Lung Cancer Study Data at American Oncology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2540779995","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540779995?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:59","pubTimestamp":1748951972,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  presented the latest results of the phase III clinical study for benmelstobart injection in combination with anlotinib hydrochloride capsules at the American Society of Clinical Oncology's annual meetingThe drug is being tested as first-line treatment for non-small cell lung cancer in comparison with the pembrolizumab injection.The study has achieved the primary study endpoint of progression-free survival, in which the median survival was prolonged by more than 6 months in the population with TPS ≥50%.There was also a 40% reduction in the risk of disease progression and death as compared with the arm of pembrolizumab.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ08YR35.GBP","BK1589","AFG","BK1521","IE00BZ08YS42.EUR","BK1191","01177","IE00BZ08YT58.USD","BK1515","BK4107","BK4117"],"gpt_icon":0},{"id":"2540076080","title":"CSPC Pharmaceutical Group Announces Breakthrough Therapy Designation for JMT101 in Advanced Colorectal Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540076080","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540076080?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:41","pubTimestamp":1748864511,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited has announced that their drug JMT101 has been granted Breakthrough Therapy Designation in China for the treatment of colorectal cancer. The designation was awarded by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China. JMT101, developed by CSPC Pharmaceutical Group, is intended for use in combination with irinotecan for treating RAS, RAF, EGFR ECD, and PIK3CA exon 20 wild-type advanced colorectal cancer after the failure of standard treatment in second-line or beyond. Clinical studies have demonstrated JMT101's breakthrough efficacy and favorable safety profile, indicating potential as a new standard treatment for later-line colorectal cancer. The company is currently conducting a pivotal phase III clinical trial of JMT101 in combination with irinotecan for this indication and is also exploring its use in multiple phase II and III trials for other solid tumors. The Breakthrough Therapy Desig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL1yVdGn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","LU1008478684.HKD","LU0880133367.SGD","LU1951186391.HKD","LU1226288253.USD","LU1960683339.HKD","LU1152091754.HKD","LU1993786604.SGD","LU1807302812.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU0072913022.USD","IE0008369823.USD","LU0326950275.SGD","BK1191","LU0067412154.USD","LU1152091168.USD","IE00BZ08YR35.GBP","LU1226287529.USD","LU1226288170.HKD","LU0140636845.USD","BK1521","BK1515","LU0501845795.SGD","IE00B543WZ88.USD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","01093","IE0008368742.USD","LU1226287875.USD","IE00B031HY20.USD"],"gpt_icon":1},{"id":"2540673807","title":"Fosun Pharma's Respiratory Drug Receives Clinical Trial Approval for COPD Treatment in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2540673807","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540673807?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:07","pubTimestamp":1748862470,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  Co.'s  independently developed small molecule oral DPP-1 inhibitor, XH-S004, has been approved for clinical trials in China for the treatment of chronic obstructive pulmonary disease .XH-S004 is also being trialed for the treatment of non-cystic fibrosis bronchiectasis, according to its Hong Kong bourse filing on Friday.As of April, the Group had invested about 61 million yuan in the research and development of XH-S004.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1230","BK1593","02196","00656","BK1191"],"gpt_icon":0},{"id":"2540762803","title":"CSPC Pharmaceutical -  Jmt101 Granted Breakthrough Therapy Designation by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2540762803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540762803?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:36","pubTimestamp":1748860596,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nFWN3S301R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0880133367.SGD","IE00BZ08YR35.GBP","IE00B543WZ88.USD","LU1951186391.HKD","LU1226287792.SGD","LU0140636845.USD","IE00BZ08YT58.USD","LU1226288170.HKD","LU1960683339.HKD","LU1226287875.USD","LU1152091168.USD","IE0008369823.USD","LU0067412154.USD","IE0008368742.USD","LU1226287529.USD","BK1521","LU1008478684.HKD","LU0072913022.USD","LU1807302812.USD","LU1152091754.HKD","LU1226288253.USD","01093","LU0326950275.SGD","BK1515","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1993786604.SGD","LU0501845795.SGD","IE00BZ08YS42.EUR","BK1191","SG9999004220.SGD"],"gpt_icon":0},{"id":"2540904757","title":"CSPC Pharmaceutical Group May Benefit From Higher Success Odds of 'SYS6010' -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2540904757","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540904757?lang=en_us&edition=fundamental","pubTime":"2025-06-02 13:41","pubTimestamp":1748842860,"startTime":"0","endTime":"0","summary":"0541 GMT - CSPC Pharmaceutical Group may benefit from higher success odds of its 'SYS6010' antibody-drug conjugate, China Galaxy International's Lily Wang says in a research report. SYS6010 has demonstrated tolerable safety and promising efficacy in both Epidermal Growth Factor Receptor-mutant and EGFR wild-type non-small cell lung cancer, the analyst notes. Also, management highlighted its business development performance in 2025 could exceed its previous guidance of 2-3 more deals, including at least three out-licensing deals worth over US$5 billion each, the analyst adds. The brokerage raises the stock's target price to HK$10.04 from HK$7.43 with an unchanged add rating. Shares are 6.2% lower at HK$7.60. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","BK1191","SG9999004220.SGD","IE0008369823.USD","LU1951186391.HKD","LU0326950275.SGD","BK1521","LU1226288253.USD","LU0067412154.USD","LU0501845795.SGD","IE00BZ08YR35.GBP","LU1226287529.USD","LU1152091168.USD","IE0008368742.USD","01093","BK1515","LU1226287875.USD","LU1960683339.HKD","LU0880133367.SGD","LU1807302812.USD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU0072913022.USD","LU1152091754.HKD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE00B031HY20.USD","LU1008478684.HKD","LU1226288170.HKD"],"gpt_icon":1},{"id":"2539275394","title":"Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275394","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539275394?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:43","pubTimestamp":1748616210,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has been involved in legal proceedings with Viking Therapeutics, Inc. over the importation of its drug candidates, ASC41 and ASC43F. In October 2024, the United States International Trade Commission issued an initial determination finding a violation of Section 337, recommending a seven-year exclusion order for these drugs. ASC41 is developed for treating non-alcoholic steatohepatitis  and targets thyroid hormone receptor beta , while ASC43F is a fixed-dose combination targeting both THRβ and farnesoid X receptor  for NASH treatment. Despite the ruling, Ascletis believes the outcome will not have a material adverse effect on its business and is seeking legal advice for an appeal. The company is committed to protecting its trade secrets and will provide updates on any significant developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL48bdv9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1574","BK4139","BK4588","BK1161","VKTX","BK1515","BK4599","BK4585"],"gpt_icon":0},{"id":"2539219128","title":"Fosun Pharmaceutical Gets Chinese Regulatory Approval for Breast Cancer Drug; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539219128","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539219128?lang=en_us&edition=fundamental","pubTime":"2025-05-30 11:19","pubTimestamp":1748575161,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Jinzhou Aohong Pharmaceutical received the approval of China's drug administrator for its citrate-formulated novel drug FCN-437c in capsule form, according to a Thursday filing with the Shanghai bourse.The approved indication is in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer following prior endocrine therapy.Shares of the pharmaceutical company rose 4% in recent trade on the Shanghai bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0187","BK0175","BK0196","BK0028","BK1230","00656","BK0239","BK0096","BK1593","BK1515","BK1191","BK0183","BK0060","BK0012","02196","600196","BK0188"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}